Iraqi Journal of Hematology

Scope & Guideline

Unveiling Breakthroughs in Blood Disorders

Introduction

Explore the comprehensive scope of Iraqi Journal of Hematology through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Iraqi Journal of Hematology in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2072-8069
PublisherWOLTERS KLUWER MEDKNOW PUBLICATIONS
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationIRAQI J HEMATOL / Iraqi J. Hematol.
Frequency2 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressWOLTERS KLUWER INDIA PVT LTD, A-202, 2ND FLR, QUBE, C T S NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra 400059, INDIA

Aims and Scopes

The Iraqi Journal of Hematology serves as a pivotal platform for disseminating research and advancements in hematology, with a strong emphasis on clinical studies and diagnostic innovations. The journal focuses on a variety of hematological conditions, treatments, and the implications of emerging research in the field.
  1. Clinical Research in Hematology:
    The journal publishes clinical studies that assess treatment outcomes, diagnostic techniques, and patient management strategies for various hematological disorders, such as leukemia, thalassemia, and lymphoma.
  2. Diagnostic Innovations:
    There is a consistent focus on the evaluation and comparison of diagnostic methods, including novel techniques for blood tests and cross-matching, which contribute to improved patient outcomes.
  3. Epidemiological Studies:
    The journal frequently includes epidemiological research that examines the prevalence and risk factors associated with hematological diseases within specific populations, particularly in Iraq.
  4. Therapeutic Interventions:
    Research on the efficacy and safety of treatment regimens, including chemotherapy, stem cell transplantation, and novel therapies, is a core area of the journal's focus.
  5. Patient-Centered Outcomes:
    Studies that explore quality of life, patient experiences, and the psychosocial aspects of living with hematological conditions are also highlighted, reflecting a comprehensive approach to patient care.
Recent publications in the Iraqi Journal of Hematology indicate a dynamic evolution of research themes, with several emerging scopes gaining traction. These trends are reflective of both global advancements and localized health concerns.
  1. Impact of COVID-19 on Hematological Patients:
    There is an increasing focus on how COVID-19 affects patients with existing hematological conditions, including complications and treatment outcomes, which is crucial given the pandemic's widespread impact.
  2. Personalized Medicine and Genetic Studies:
    Emerging research on the genetic factors influencing treatment responses in hematological diseases underscores a growing interest in personalized medicine, aiming to tailor treatments based on individual genetic profiles.
  3. Nutritional and Environmental Factors:
    Recent studies evaluating the role of nutritional deficiencies, such as Vitamin D levels in thalassemia patients, highlight a trend towards understanding how environmental and lifestyle factors affect hematological health.
  4. Innovative Therapeutics and Treatment Regimens:
    There is a marked increase in studies assessing novel therapies and regimens for hematological diseases, reflecting ongoing advancements in treatment methodologies and patient management.
  5. Quality of Life and Patient Experience Research:
    An emerging theme is the assessment of quality of life and psychosocial factors among patients with hematological disorders, emphasizing the importance of holistic patient care.

Declining or Waning

While the Iraqi Journal of Hematology continues to thrive in several areas, certain themes are becoming less prominent over time, reflecting shifts in research focus and clinical priorities.
  1. Basic Science Research:
    There is a noticeable decrease in the number of publications focusing on the fundamental biological and molecular mechanisms underlying hematological diseases, suggesting a shift towards more clinically relevant studies.
  2. Rare Hematological Disorders:
    Research on rare hematological conditions appears to be declining, possibly due to a reduced number of cases and the challenges associated with studying these less common disorders.
  3. Historical and Longitudinal Studies:
    The journal has seen fewer studies that focus on historical perspectives or long-term outcomes of hematological treatments, indicating a preference for current and immediate clinical applications.

Similar Journals

Journal of Blood Medicine

Pioneering Discoveries: Shaping the Future of Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

Experimental Hematology & Oncology

Pioneering Insights in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Indian Journal of Hematology and Blood Transfusion

Empowering Healthcare Through Cutting-edge Hematology Research
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

AMERICAN JOURNAL OF HEMATOLOGY

Empowering Discoveries in Blood Disorders
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Journal of Hematology

Bridging Knowledge Gaps in Hematology
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

Hematology-American Society of Hematology Education Program

Navigating the Future of Hematology Together
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Case Reports in Hematology

Elevating hematology with shared clinical insights.
Publisher: HINDAWI LTDISSN: 2090-6560Frequency: 1 issue/year

Case Reports in Hematology, published by HINDAWI LTD, stands as a prominent open-access journal dedicated to disseminating innovative case reports that contribute significantly to the field of hematology. Established in 2011, this journal provides a vital platform for researchers, practitioners, and clinicians to share detailed observations and novel findings related to blood disorders and treatment responses. With its commitment to high-quality research and accessibility, Case Reports in Hematology aims to enhance the understanding of hematological conditions, fostering collaboration and dialogue among professionals in the discipline. By leveraging an open-access model, the journal ensures that its valuable content is readily available to a global audience, consequently promoting advanced research and improving patient care in hematology. As a testament to its academic rigor and relevance, the journal appeals to its readership, which includes researchers, healthcare professionals, and students eager to expand their knowledge and insights into this critical area of medicine.

Blood and Lymphatic Cancer-Targets and Therapy

Pioneering Insights into Blood and Lymphatic Cancer
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

Egyptian Journal of Haematology

Elevating Expertise in Blood Disorders and Transfusion Medicine
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

LEUKEMIA & LYMPHOMA

Fostering innovation in cancer diagnostics and therapies.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.